Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 16, 2016 ) The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment options include drugs not already used during past treatment and conditioning therapy followed by transplantation.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Refractory Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 34, 39, 1, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 6 and 1 molecules, respectively.Refractory Acute Myeloid Leukemia.
Refractory Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/refractory-acute-myeloid-leukemia-pipeline-review-h2-2016
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia (Oncology). - The pipeline guide reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Refractory Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Refractory Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492626/sample
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
AVEO Pharmaceuticals Inc Bellicum Pharmaceuticals Inc Bio-Cancer Treatment International Ltd BioLineRx Ltd BioSight Ltd Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc Celgene Corp Cornerstone Pharmaceuticals Inc CSPC Pharmaceutical Group Limited CTI BioPharma Corp Daiichi Sankyo Company Ltd Eisai Co Ltd Eli Lilly and Company EpiZyme Inc Exelixis Inc F. Hoffmann-La Roche Ltd Fate Therapeutics Inc FLX Bio, Inc. FORMA Therapeutics Inc Fujifilm Corp GlaxoSmithKline Plc GlycoMimetics Inc Igenica Biotherapeutics Inc Incyte Corp Io Therapeutics Inc JW Pharmaceutical Corp
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492626/discount
List of Figures
Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016 19 Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2016 20 Number of Products under Development by Companies, H2 2016 21 Number of Products under Investigation by Universities/Institutes, H2 2016 25 Comparative Analysis by Late Stage Development, H2 2016 26 Comparative Analysis by Clinical Stage Development, H2 2016 27 Comparative Analysis by Early Stage Products, H2 2016 28 Assessment by Monotherapy Products, H2 2016 96 Number of Products by Top 10 Targets, H2 2016 98 Number of Products by Stage and Top 10 Targets, H2 2016 98 Number of Products by Top 10 Mechanism of Actions, H2 2016 106 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 106 Number of Products by Routes of Administration, H2 2016 114 Number of Products by Stage and Routes of Administration, H2 2016 114 Number of Products by Molecule Types, H2 2016 116 Number of Products by Stage and Molecule Types, H2 2016 116
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001492626/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|